| Name | Afatinib |
|---|---|
| Synonyms |
N-4-(3-Chloro-4-fluorophenyl)amino-7-(3S)-tetrahydro-furan-3-yloxy-6-quinazolinyl-4-(dimethylamino)but-2-enamide
(E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide Tovok (E/Z)-BIBW2992 (E/Z-Afatinib) Afatinib //BP (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran- 3-yl)oxy)quinazolin-6-yl)-4-(diMethylaMino)but-2-enaMide [14C] (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dim Afatinib (BIBW 2992)r (E/Z)-Afatinib Afatinib(W.S) (2E)-N-(4-[(3-chloro-4-fluorophenyl)amino]-7-{[(3S)-tetrahydrofuran-3-yl]oxy}quinazolin-6-yl)-4-(dimethylamino)but-2-enamide BIBW-2292 Afatinib, >= BIBW2992 Afatinib ToMtovok (2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydro-3-furanyloxy]-6-quinazolinyl}-4-(dimethylamino)-2-butenamide Tovok, BIBW (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimeth (S,E)-N-(4-(3-chloro-4-fluorophenylaMino)-7-(tetrahydrofuran-2-yloxy)quinazolin-6-yl)-4-(diMethylaMino)but-2-enaMide Afatinb (S)-Afatinib, 10 mM in DMSO Afatinib Base 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino) The method for Tomtovok BIBW2992 N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide BIBW 2992;TOVOK (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dim Alfatinib (S,E)-N-(4-(3-chloro-4-fluorophenylaMino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(diMethylaMino)but-2-enaMide Gilotrif (S)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[(3-tetrahydrofuranyl)oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide Tofacitinib and its interMediate BIBW 2992 TOVOK (BIBW-2992, Afatinib) Medicine ade Afatinib Cancer Treatment Afatinib CAS BIBW 2992 N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide Afatinib(cis-trans isomerismtautomers) N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide Offer 439-2 Afatinib Afatinib powder AFATINIB; BIBW2992;BIBW-2292 (E)-N-(7-((S)-tetrahydrofuran-3-yloxy)-4-(3-chloro-4-fluorophenylaMino)quinazolin-6-yl)-4-(diMethylaMino)but-2-enaMide [14C]Afatinib (S)-Afatinib (S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide Afatinib, Free Base |
| Description | (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells[1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 676.9±55.0 °C at 760 mmHg |
| Melting Point | 100 - 102 °C |
| Molecular Formula | C24H25ClFN5O3 |
| Molecular Weight | 485.94 |
| Flash Point | 363.2±31.5 °C |
| Exact Mass | 485.162994 |
| PSA | 88.61000 |
| LogP | 3.59 |
| Vapour Pressure | 0.0±2.1 mmHg at 25°C |
| Index of Refraction | 1.668 |
| Storage condition | -20°C |
| Hazard Codes | Xn |
|---|---|
| HS Code | 2934999090 |
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |